He discovered the energy molecule that runs every cell in every living thing on Earth. Then he invented the first chemotherapy drug. Then the first tetracycline antibiotic. Harvard denied him tenure. A bowling alley wouldn’t let him bowl. He died at 53 with no obituary.

His drugs save tens of millions of lives every year. Most doctors prescribing them don’t know his name.

His name was Yellapragada

He was born in 1895 in Bhimavaram, India — a village. His father was a Sanskrit scholar who died of tropical sprue. The disease killed two of his brothers too. Subbarow watched them waste away as a child and made a decision that would define the rest of his life: he was going to fight disease.

He failed his school exams twice. He matriculated on the third try. His future father-in-law paid for his medical school books. Subbarow married the man’s daughter and repaid the debt.

In October 1922, he arrived in Boston with broken English and borrowed money. He was 27 years old. He got into Harvard Medical School. Then into the biochemistry PhD program. He began working under a senior researcher named Cyrus Fiske. The hours were long. The pay was low. He was at Harvard. He didn’t care.

In 1925, Fiske and Subbarow developed the Fiske-SubbaRow assay — the method for measuring phosphorus in body fluids. It is still used today for kidney failure, vitamin D testing, and prostate cancer. It became one of the most cited methods in the history of biochemistry.

Then they discovered something bigger.

In the late 1920s, Subbarow and Fiske identified and isolated ATP — adenosine triphosphate — the energy molecule that powers every cell in every living organism on Earth. The discovery rewrote biochemistry. It also proved that the prevailing understanding of how muscles work, derived from Nobel Prize-winning research, was incomplete. Muscles don’t run on glycogen alone. They run on ATP.

Subbarow received his PhD in 1930.

He stayed at Harvard for another decade. Paper after paper. Discovery after discovery. And every year, Harvard refused to promote him. The biochemistry department had never given tenure to a foreign-born scientist. They were not going to start with an Indian.

His colleagues took him fishing. Played tennis with him. Came to dinner at his house. Then voted against him at every promotion review.

Outside the lab, he hit the same wall. He bought an airplane and learned to fly because he loved it. He tried bowling once. The local alley turned him away. The sign said the facility was open only to the Caucasian race.

Then Fiske turned on him. The senior researcher began blocking Subbarow’s discoveries out of professional jealousy. Some of Subbarow’s findings had to be independently rediscovered years later by other scientists, because Fiske kept them buried in unpublished files.

In May 1940, Harvard denied him tenure for the final time. After 17 years of groundbreaking work, he walked out.

Lederle Laboratories in Pearl River, New York, hired him as Associate Director of Research. He was Director of the entire research division by the end of the year.

In the eight years that followed, he did the following.

He developed diethylcarbamazine — an oral drug that killed the tropical parasitic worms that were crippling American soldiers across the Pacific theater of World War II. The World Health Organization still uses it today as a first-line treatment.

He isolated folic acid from liver tissue and developed the process to mass-produce it. Folic acid supplementation during pregnancy now prevents neural tube birth defects in tens of millions of pregnancies every year. The same disease family — nutritional deficiency — that had killed his father and his brothers became preventable because of him.

Then Dr. Sidney Farber called from Boston with a theory. Farber believed that a drug capable of blocking folic acid specifically in rapidly dividing cancer cells might be able to kill childhood leukemia. He needed someone who could make the drug.

Subbarow’s team made it. They called it Aminopterin.

In December 1947, Farber administered Aminopterin to an 8-year-old boy who was dying of acute lymphoblastic leukemia. Within weeks, the cancer cells began to disappear. The boy went into remission.

It was the first time in history that a drug had put cancer into remission.

It was the first chemotherapy drug ever used.

Subbarow’s team refined the compound into Amethopterin — now known worldwide as methotrexate. It became the gold standard treatment for leukemia, lymphoma, breast cancer, and lung cancer. It is also now used for rheumatoid arthritis, psoriasis, and Crohn’s disease. The World Health Organization lists it as an essential medicine. Tens of millions of people take it every single year.

In 1948, Subbarow’s laboratory produced Aureomycin — the first tetracycline antibiotic ever developed. It was broad-spectrum: capable of killing typhus, cholera, pneumonia, and dozens of bacterial infections that penicillin couldn’t touch. It opened an entirely new class of antibiotics that includes doxycycline and minocycline — drugs used today against plague, malaria, anthrax, and drug-resistant bacterial infections around the world.

He was 53 years old. He had spent his career creating drugs that would save tens of millions of lives.

On August 8, 1948, Yellapragada Subbarow had a heart attack at his home in New York and died.

No American newspaper ran a front-page obituary. No university held a memorial service. The Nobel Committee never honored him. His own colleague George Hitchings later won the 1988 Nobel Prize in Physiology or Medicine for work built directly on Subbarow’s biochemical foundation. Subbarow was not even nominated.

In 1950, Argosy magazine ran a feature about him titled Miracle Man of the Miracle Drugs. It opened with a line that still lands: “You’ve probably never heard of Dr. Yellapragada SubbaRow. Yet because he lived you may be alive and are well today. Because he lived you may live longer.”

Most Americans hadn’t heard of him in 1950. Most still haven’t.

Harvard has never officially honored him. American medical schools mostly don’t teach his name. The Nobel committee that awarded a prize for derivative work never went back to correct the record. Every prescription of methotrexate written today is silent about whose work made it possible.

India remembers. The government issued a postage stamp on what would have been his 100th birthday in 1995. His childhood home in Bhimavaram is a museum. Indian medical schools teach his name.

The country that denied him tenure, refused to let him bowl, and let him die unknown — the country that takes his drugs every single day — still mostly doesn’t know him.

Here is the thing.

If you have ever taken methotrexate for cancer or an autoimmune disease — that was him.

If anyone you love has ever taken folic acid during pregnancy — that was him.

If you have ever been prescribed doxycycline for an infection — that was him.

Yellapragada Subbarow. Born 1895. Died 1948. Saved tens of millions of lives in a country that still doesn’t know it owes him.

Now you do. Say his name.